<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910725</url>
  </required_header>
  <id_info>
    <org_study_id>19HH4965</org_study_id>
    <nct_id>NCT03910725</nct_id>
  </id_info>
  <brief_title>Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death</brief_title>
  <acronym>EPORVA</acronym>
  <official_title>Electrophysiological Remodelling Secondary to Metabolic, Inflammatory and Cardiomyopathic Processes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity, rheumatoid arthritis (RA) and gene-specific dilated cardiomyopathy (DCM) are common&#xD;
      medical conditions. Small-scale studies have shown that these are associated with&#xD;
      proarrhythmic changes on 12-lead electrocardiogram (ECG) and a higher risk of sudden cardiac&#xD;
      death (SCD). However, these studies lack the deep electrophysiological phenotyping required&#xD;
      to explain their observations. Electrocardiographic imaging (ECGi) is a non-invasive&#xD;
      alternative to 12-lead ECG, by which epicardial potentials, electrograms and activation&#xD;
      sequences can be recorded to study adverse electrophysiological modelling in greater depth&#xD;
      and on a more focussed, subject-specific scale. Therefore, this study proposes to better&#xD;
      define the risk of arrhythmia and understand the underlying adverse electrophysiological&#xD;
      remodelling conferring this risk in three groups (obesity, RA and DCM). Firstly, data from&#xD;
      two large, national repositories will be analysed to identify associations between routine&#xD;
      clinical biomarkers and proarrhythmic 12-lead ECG parameters, to confirm adverse&#xD;
      electrophysiological remodelling and a higher risk of arrhythmia. Secondly,ECGi will be&#xD;
      performed before and after planned clinical intervention in obese and RA patients, and at&#xD;
      baseline in titin-truncating variant (TTNtv)-positive and -negative DCM patients, to&#xD;
      characterise the specific and potentially reversible conduction and repolarisation&#xD;
      abnormalities that may underlie increased arrhythmic risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sudden cardiac death (SCD) occurs in groups that are neither traditionally considered&#xD;
      high-risk nor have been the subject of large-scale studies. These include obesity,&#xD;
      inflammatory arthropathy and gene-specific cardiomyopathy. Existing data to explain higher&#xD;
      risk of arrhythmia in these cohorts rely on 12-lead ECG and therefore lack in-depth&#xD;
      electrophysiological phenotyping. The investigators have access to the two large national&#xD;
      data repositories providing a wealth of data to study risks of arrhythmia on a scale larger&#xD;
      than any previously published study. They also have a proven track record of utilising&#xD;
      electrocardiographic imaging (ECGi) to conduct in-depth investigation of electrophysiological&#xD;
      remodelling to better characterise arrhythmic risk.&#xD;
&#xD;
      ECGi is a validated, noninvasive method of acquiring body surface potential data using&#xD;
      252-electrodes and combining it with subjectspecific heart-torso geometry from crosssectional&#xD;
      imaging. Using inverse solution mathematical algorithms, the ECGi system reconstructs&#xD;
      epicardial unipolar electrograms and panoramic activation and potential maps over a single&#xD;
      sinus beat, which is visualised on a digitised image of the subject's heart. Various studies&#xD;
      have demonstrated the efficacy of ECGi to localise ventricular arrhythmias; more accurately&#xD;
      calculate QT interval dispersion than 12-lead ECGs in obesity; and characterise ventricular&#xD;
      tachycardia (VT) with intramural re-entry following myocardial infarction-induced scarring.&#xD;
&#xD;
      The study aims to confirm that obesity, RA and DCM are risk factors for arrhythmia and&#xD;
      associated with electrophysiological remodelling manifest on 12-lead ECG, using large data&#xD;
      repositories. The investigators will also perform electrocardiographic imaging (ECGi) to&#xD;
      investigate and understand specific, and potentially reversible, conduction and&#xD;
      repolarisation abnormalities conferring risk of arrhythmia in these cohorts using ECGi.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Routine clinical biomarkers correlate with proarrhythmic 12-lead ECG parameters&#xD;
&#xD;
        2. Adverse (proarrhythmic) electrophysiological remodelling can be quantified with ECGi&#xD;
&#xD;
        3. Bariatric surgery reverses adverse electrophysiological remodelling in obesity&#xD;
&#xD;
        4. Pharmacological therapy reverses adverse electrophysiological remodelling in RA&#xD;
&#xD;
        5. TTNtv is associated with adverse electrophysiological remodelling in DCM&#xD;
&#xD;
      In-keeping with hypothesis 1, the study population will include participants from the UK&#xD;
      biobank and Airwave Health Monitoring Study in which risk of arrhythmia will be defined.&#xD;
      Participants in both data repositories provided informed consent for their data to be used&#xD;
      for research.&#xD;
&#xD;
      With respect to hypotheses 2-5, the study will involve 3 distinct ECGi sub-studies, each in a&#xD;
      well-defined cohort to identify specific, and potentially reversible, conduction and&#xD;
      repolarisation abnormalities, and comparing the disease to healthy controls. These are:&#xD;
&#xD;
      i. Obesity (BMI &gt;40) ii. RA iii. TTNtv-positive and -negative DCM&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Activation-recovery intervals</measure>
    <time_frame>30 months approximately ie at the end of the study</time_frame>
    <description>Electrocardiographic parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conduction velocity</measure>
    <time_frame>30 months approximately ie at the end of the study</time_frame>
    <description>Electrocardiographic parameter</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Sudden Cardiac Death</condition>
  <condition>Cardiomyopathy, Dilated</condition>
  <condition>Obesity</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Obesity</arm_group_label>
    <description>Patients with BMI &gt;40 awaiting stapled bariatric surgery, without a history of or concomitant ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be recruited prospectively from the bariatric surgery preoperative assessment clinics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <description>Patients with RA without diagnosed or known ischaemic or structural heart disease, arrhythmia or receiving anti-arrhythmic medication will be recruited prospectively from rheumatology clinics, prior to initiation of biologic or diseased modifying anti-rheumatic drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dilated cardiomyopathy</arm_group_label>
    <description>TTNtv-positive and -negative DCM patients from the Royal Brompton Hospital biobank have provided informed consent to be contacted for research</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electrocardiographic imaging</intervention_name>
    <description>ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.</description>
    <arm_group_label>Dilated cardiomyopathy</arm_group_label>
    <arm_group_label>Obesity</arm_group_label>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients awaiting stapled bariatric surgery, without a history of or concomitant ischaemic&#xD;
        or structural heart disease, arrhythmia or receiving anti-arrhythmic medication, will be&#xD;
        recruited prospectively from the bariatric surgery preoperative assessment clinics.&#xD;
&#xD;
        Similarly, patients with RA will be recruited prospectively from rheumatology clinics,&#xD;
        prior to initiation of biologic or diseased modifying anti-rheumatic drugs. TTNtv-positive&#xD;
        and -negative DCM patients an existing data registry will be recalled for this study.&#xD;
        Healthy volunteers: will be recruited from our affiliated institutions who have given prior&#xD;
        consent to be contacted for research.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with obesity (BMI&gt;40) who will undergo stapled bariatric surgery&#xD;
&#xD;
          -  RA, prior to commencement of disease-modifying drugs&#xD;
&#xD;
          -  TTNtv-positive or -negative DCM&#xD;
&#xD;
          -  no known existing medical condition or health concerns i.e. healthy volunteers;&#xD;
&#xD;
          -  aged 18 to 75 years, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aged under 18 or over 75 years;&#xD;
&#xD;
          -  known HIV, hepatitis B &amp; C or vCJD infection;&#xD;
&#xD;
          -  unable to provide verbal or signed written informed consent;&#xD;
&#xD;
          -  pregnancy or positive urinary pregnancy test;&#xD;
&#xD;
          -  breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu Siong Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fu Siong Ng, BSc MRCP PhD</last_name>
    <phone>+442075943614</phone>
    <email>f.ng@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiran HK Patel, BSc MRCP</last_name>
    <phone>07563225319</phone>
    <email>kiran.patel@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial College London (Hammersmith campus)</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu Siong Ng</last_name>
      <phone>02075943614</phone>
      <email>f.ng@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kiran Patel</last_name>
      <phone>07563225319</phone>
      <email>kiran.patel@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fu Siong Ng</last_name>
      <phone>02075943614</phone>
      <email>f.ng@imperial.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kiran Patel</last_name>
      <phone>02075943614</phone>
      <email>kiran.patel@imperial.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Cardiomyopathy, Dilated</keyword>
  <keyword>Electrocardiographic imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Death, Sudden, Cardiac</mesh_term>
    <mesh_term>Cardiomyopathy, Dilated</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Death</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only anonymised data will be shared amongst the research team. This includes electrocardiographic, imaging, demographic, biochemical and other clinical data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03910725/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03910725/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

